Publications by authors named "M Bustoros"
Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase II trial (NCT02916771) evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with HR-SMM. The primary endpoint, median progression-free survival (PFS), was not reached (NR) (95% CI: 57.
View Article and Find Full Text PDFArticle Synopsis
- BCMA-targeting CAR-T cells are now a key treatment for relapsed/refractory multiple myeloma, with patient outcomes linked to T cell expansion post-infusion.
- A study involving 156 patients found that those with higher maximum absolute lymphocyte count (ALCmax) showed significantly improved depth of response and progression-free survival.
- ALCmax over 1.0 × 10^3/μL correlates with better outcomes, while lower counts indicate a higher risk of disease progression, suggesting ALC can serve as an important prognostic marker.
Background: Early therapeutic intervention in high-risk SMM (HR-SMM) has demonstrated benefit in previous studies of lenalidomide with or without dexamethasone. Triplets and quadruplet studies have been examined in this same population. However, to date, none of these studies examined the impact of depth of response on long-term outcomes of participants treated with lenalidomide-based therapy, and whether the use of the 20/2/20 model or the addition of genomic alterations can further define the population that would benefit the most from early therapeutic intervention.
View Article and Find Full Text PDFBiomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia.
Hematol Oncol Clin North Am
August 2023
Article Synopsis
- - Waldenström macroglobulinemia is a slow-growing type of cancer that affects B-cells and produces IgM antibodies; it often starts with an asymptomatic phase.
- - Researchers have developed risk models using both specific and general biomarkers to predict how quickly different patients may progress from the asymptomatic stage.
- - Newer models are incorporating continuous variables and genetic alterations, which may enhance the accuracy of risk prediction and improve the management of asymptomatic individuals.
Peripheral blood smear (A) demonstrates increased numbers of plasma cells (representative cells indicated by arrows), (B) demonstrates polytypic nature of plasma cells.
View Article and Find Full Text PDF